SINOMED(SH:688108) Zheng Quan Shi Bao Wang·2025-09-04 10:18Core Viewpoint - Sino Medical (688108) has received regulatory measures from Tianjin Securities Regulatory Bureau due to inaccuracies in financial disclosures, specifically related to accounting errors that led to a misstatement of investment income and net profit [1][2] Group 1: Regulatory Actions - The Tianjin Securities Regulatory Bureau issued a decision requiring Sino Medical to correct its financial disclosures and imposed regulatory talks on Chairman Sun Jianhua and CFO Shen Lihua for their lack of diligence [2] - Sino Medical acknowledges the issues raised in the regulatory decision and commits to internal accountability, enhancing financial management, and improving information disclosure quality to prevent future violations [2] Group 2: Financial Performance - For the first half of 2025, Sino Medical reported total revenue of 240 million yuan, a year-on-year increase of 12.53%, driven by a 17.40% growth in coronary intervention business revenue due to increased sales of newly included products [3] - The company achieved a total profit of 23.01 million yuan, a significant increase of 585.93% compared to the previous year, attributed to revenue growth and a decrease in sales and R&D expenses [3] - The net profit attributable to shareholders was 13.84 million yuan, reflecting a 296.54% increase year-on-year, influenced by the substantial rise in total profit and a 299.98% increase in income tax expenses [3]